SuperworthenGene Therapeutics market cap ENGN
Share price times shares outstanding: what the whole company sells for, since 2024.
- Today, Oct 23, 2026
- $104.5M
- Highest close in our data
- $815.2M
- Jan 2026
enGene Therapeutics is worth $104.5M at the close on Oct 23, 2026, at $1.56 a share.
That is down 75% over the last year.
Its highest close in our data was $815.2M in Jan 2026.
Market cap over time
Year by year
| Year | End of year | Low | High | Change |
|---|---|---|---|---|
| 2026 so far | $104.5M | $100.5M | $815.2M | −84% |
| 2025 | $636.4M | $150.9M | $636.4M | +94% |
| 2024 | $327.3M | $179.8M | $783.6M | n/a |
Against its peers
Companies in Healthcare nearest enGene Therapeutics' size, closest first, today.
| Company | Market cap |
|---|---|
| ENGNenGene Therapeutics | $104.5M |
| KEQUKewaunee Scientific | $94.9M |
| ICCCImmucell | $93.1M |
| LFVNLifevantage | $73.4M |
| SPROSpero Therapeutics | $64.6M |
| APTAlpha Pro Tech | $56.7M |
| PDEXPro DEX | $199.3M |
| PLXProtalix BioTherapeutics | $205.5M |
| NATRNatures Sunshine Products | $213.8M |
| ELMDElectromed | $220.6M |
| ATNMActinium Pharmaceuticals | $47.8M |
| Peer median | $94M |
What the market cap tells you
Share price times shares outstanding: what the whole company sells for today.
Size, not quality. Large caps move slower and are covered more. That is all it tells you.
More on enGene Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.